Karen Hunt, MD
Family Medicine · Lawrence, MANPI 1891799524
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 506 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,983 and has fallen 76.1% since, to $474 in 2025. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 506 payments — averaging $16.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$1K
- Pfizer$1K
- GSK$594
- Novo Nordisk$542
- Teva Pharmaceuticals USA, Inc.$405
- plus $3K from 24 others
What the payments were for
- Food & beverage$8,235100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 83 | $1,594 |
| AstraZeneca | 59 | $1,099 |
| Pfizer | 87 | $1,010 |
| GSK | 28 | $594 |
| Novo Nordisk | 31 | $542 |
| Teva Pharmaceuticals USA, Inc. | 54 | $405 |
| Lilly USA, LLC | 27 | $388 |
| Boehringer Ingelheim | 18 | $364 |
| Merck | 15 | $238 |
| Novartis | 16 | $237 |
| Biohaven Pharmaceuticals, Inc. | 10 | $221 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $203 |
| Amgen | 10 | $169 |
| Johnson & Johnson | 8 | $150 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $133 |
| Gilead | 6 | $124 |
| E.r. Squibb & Sons, L.L.C. | 3 | $101 |
| Hologic Sales And Service, LLC | 4 | $84 |
| Astellas Pharma US Inc | 4 | $80 |
| Eisai Inc. | 4 | $78 |
| Genentech USA, Inc. | 5 | $69 |
| Inspire Medical Systems, Inc. | 2 | $51 |
| Redhill Biopharma Inc. | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Bayer | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $15 |
| Viiv Healthcare Company | 1 | $14 |
How this compares
$8,235 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 109 | $136,313 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $42,249 |
| JanuviaSitagliptin Phosphate | 43 | $33,098 |
| XareltoRivaroxaban | 24 | $29,213 |
| EliquisApixaban | 26 | $28,318 |
| OzempicSemaglutide | 30 | $26,233 |
| LinzessLinaclotide | 38 | $21,398 |
| VraylarCariprazine Hcl | 14 | $21,127 |
| JardianceEmpagliflozin | 20 | $20,102 |
| MounjaroTirzepatide | 15 | $14,798 |
| FarxigaDapagliflozin Propanediol | 13 | $13,054 |
| Arnuity ElliptaFluticasone Furoate | 37 | $10,885 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $7,221 |
| Spiriva HandihalerTiotropium Bromide | 13 | $7,040 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $7,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $388 | $151,111124 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta | $594 | $60,165115 claims |
| AbbVieLinzess, Vraylar | $1,594 | $42,52452 claims |
| MerckJanuvia | $238 | $33,09843 claims |
| Johnson & JohnsonXarelto | $150 | $29,21324 claims |
| PfizerEliquis | $1,010 | $28,31826 claims |
| Novo NordiskOzempic | $542 | $26,23330 claims |
| Boehringer IngelheimJardiance | $364 | $20,10220 claims |
| AstraZenecaFarxiga | $1,099 | $13,05413 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler | $405 | $5,05524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Other family medicine in Lawrence
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Elie AtaLawrence$7K
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.